Additive hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
Background & Aim: Resmetirom (THR-β receptor agonist) has recently been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and semaglutide (GLP-1R agonist) is in late-stage clinical development for treatment of MASH. The present study aimed to characterize metabolic, biochemical,…
Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
GAN DIO-MASH model is top-ranked by the LITMUS consortium: read more
Renal cell-type associated therapeutic effects of semaglutide in a mouse model of hypertension accelerated diabetic kidney disease
Background & Aim Obesity, hyperglycemia and hypertension are critical risk factors for development of diabetic kidney disease (DKD). While emerging evidence suggests that glucagon-like peptide-1 receptor (GLP-1R) agonists improve cardiovascular and renal outcomes in type 2 diabetes patients, their mode…
